帕博利珠单抗序贯AVD方案治疗初治早期不良及晚期经典型霍奇金淋巴瘤
这项多中心单臂2期试验评估了帕博利珠单抗单药序贯AVD化疗在初治早期不良或晚期经典型霍奇金淋巴瘤中的完全代谢缓解率与安全性。30例患者接受3周期帕博利珠单抗后序贯4至6周期AVD,单药后37%达完全代谢缓解,全部患者2周期AVD后达完全代谢缓解且末次治疗维持缓解,中位随访22.5个月无治疗变更、进展或死亡。
要点
- 帕博利珠单抗单药3周期后37%患者达完全代谢缓解。
- 全部患者2周期AVD后达完全代谢缓解并维持至治疗结束。
- 中位随访22.5个月无进展或死亡,未行巩固放疗。
核心结论
- 短程帕博利珠单抗单药序贯AVD在初治经典型霍奇金淋巴瘤中高效且安全,包括大肿块病患者。
研究设计与样本
- 多中心、单臂、研究者发起的2期试验,纳入30例初治早期不良(n=12)或晚期(n=18)经典型霍奇金淋巴瘤患者。
- 患者接受3周期帕博利珠单抗单药,后续AVD化疗4至6周期,取决于分期和肿块大小。
- 12例患者有大纵隔肿块或肿块>10 cm。
主要发现
- 帕博利珠单抗单药后11例(37%)达完全代谢缓解。
- 28例可量化PET-CT患者中额外7例(25%)代谢肿瘤体积缩小>90%。
- 全部患者2周期AVD后达完全代谢缓解,并维持至治疗结束。
- 中位随访22.5个月(范围14.2-30.6),无治疗变更、进展或死亡。
- 无患者接受巩固放疗,包括大肿块病患者。
关键数值与推荐
- 帕博利珠单抗单药后完全代谢缓解率为37%(11/30)。
- 可量化PET-CT患者中25%(7/28)代谢肿瘤体积缩小>90%。
临床怎么用
- 初治早期不良或晚期经典型霍奇金淋巴瘤可考虑帕博利珠单抗短程单药序贯AVD,大肿块病患者亦可能免于巩固放疗。
局限性
- 单臂设计、样本量小(30例),随访时间较短(中位22.5个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pembrolizumab, a humanized IgG4 monoclonal antibody targeting programmed death-1 protein, has demonstrated efficacy in relapsed/refractory classical Hodgkin lymphoma (cHL). To assess the complete metabolic response (CMR) rate and safety of pembrolizumab monotherapy in newly diagnosed cHL, we conducted a multicenter, single-arm, phase 2 investigator-initiated trial of sequential pembrolizumab and doxorubicin, vinblastine, and dacarbazine (AVD) chemotherapy. Patients ≥18 years of age with untreated, early, unfavorable, or advanced-stage disease were eligible for treatment. Thirty patients (early unfavorable stage, n = 12; advanced stage, n = 18) were treated with 3 cycles of pembrolizumab monotherapy followed by AVD for 4 to 6 cycles, depending on stage and bulk. Twelve had either large mediastinal masses or bulky disease (>10 cm). After pembrolizumab monotherapy, 11 patients (37%) demonstrated CMRs, and an additional 7 of 28 (25%) patients with quantifiable positron emission tomography computed tomography scans had >90% reduction in metabolic tumor volume. All patients achieved CMR after 2 cycles of AVD and maintained their responses at the end of treatment. With a median follow-up of 22.5 months (range, 14.2-30.6) there were no changes in therapy, progressions, or deaths. No patients received consolidation radiotherapy, including those with bulky disease. Therapy was well tolerated. The most common immune-related adverse events were grade 1 rash (n = 6) and grade 2 infusion reactions (n = 4). One patient had reversible grade 4 transaminitis and a second had reversible Bell's palsy. Brief pembrolizumab monotherapy followed by AVD was both highly effective and safe in patients with newly diagnosed cHL, including those with bulky disease. This trial was registered at www.clinicaltrials.gov as #NCT03226249.
引用
- Allen PB, Savas H, Evens AM, et al. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. Blood. 2021. PMID: 32992341. doi:10.1182/blood.2020007400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。